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Background: To compare prospectively the diagnostic efﬁcacies for 
determining TNM stages of integrated PET/CT and 3T whole-body MR 
imaging (WB MRI) in non-small cell lung cancer (NSCLC).
Methods: Our study included 155 patients (M: F = 120:35, mean; 
61 ± 11 years) with pathologically proven NSCLC who underwent 
both integrated PET/CT and WB MRI. After acquiring dedicated lung 
images (breath-hold triple inversion black blood [TIBB] T2W turbo 
spin-echo [TSE] and T1W Turbo-ﬁeld echo [TFE] images), WB MRI 
(composed of 8 stacks of coronal images) was performed by using 
T2W TSE and pre- and post-contrast enhanced T1W TFE sequences. 
At PET/CT, abnormal uptakes were regarded present when suspected 
lesions demonstrated discrete FDG uptake at a level greater than that of 
surrounding tissues. At MRI, nodes showing high-signal intensity with 
eccentric cortical thickening or obliterated fatty hilum on T2W images 
were considered malignant. Discrete lesions with high signal intensity 
on T2W TSE images were considered metastatic, if they demonstrated 
signiﬁcant enhancement on T1W TFE images. Pathology for T (n = 
125) and N (n = 142) stage determination, and pathology or follow-up 
imaging studies (n = 149) for M staging served as reference standards. 
Findings: Primary tumor (n = 125) was correctly staged in 99 patients 
(79%) at PET/CT and in 103 patients (82%) at WB MRI (p = 0.572, 
the McNemar test). N stage (n = 142) was correctly determined in 98 
(69%) patients at PET/CT and in another 98 (69%) at WB MRI (p = 
1.000). Fourteen (M1, 9%) of 149 patients had 23 metastatic lesions. 
Accuracy for detecting metastases was 93% (138 of 149) at PET/CT, 
whereas that at WB MRI was 95% (142 of 149) (p = 0.388). WB MRI 
was more useful for detecting brain metastases, whereas PET/CT for 
soft-tissue metastases.
Interpretation: Both 3T WB MRI and PET/CT appear to provide ac-
ceptable accuracy and comparable efﬁcacy in NSCLC staging, but in 
M stage determination, they have different advantages from each other. 
Therefore, whole body MR/PET may be the future imaging modality 
for NSCLC staging.
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Background: This study was performed to validate the efﬁcacy of 
FLT-positron emission tomography (PET) as a noninvasive tumor 
proliferation imaging method and the safety of FLT as a diagnostic 
radiopharmaceutical. 
Methods: A prospective, nonrandomized, phase III clinical trial was 
performed in a single center. Adult (>18 yr) patient(pt)s with primary 
lung cancer with > 1.5 cm in size, scheduled to surgery after staging 
work-up were eligible. Before surgery, FLT-PET images of chest ﬁeld 
were obtained using a PET/CT scanner at 1 hr after injection of 370 
MBq FLT. Standardized uptake values (SUV) of tumor were measured 
using a threshold (80% of maxSUV) deﬁned volume of interest. After 
surgery, Ki-67 values of tumor were measured by two pathologists who 
were blind to FLT-PET results. The primary endpoint of this study was 
a good correlation between the measurements of tumor proliferation by 
SUVs using FLT-PET and Ki-67 values (H0; ρ ≤ 0.5 vs H1; ρ > 0.5, 
p < 0.05). In a statistical consideration, the necessary sample size was 
88 pts, and we enrolled total of 110 pts considering possible 20% drop 
rate. The secondary endpoint was no severe adverse reaction related to 
FLT, which was monitored before and after administration of FLT. 
Results: Among 110 pts, data form 93 pts were analyzed after exclu-
sion of 17 pts due to various reasons according to the protocol (techni-
cally inadequate images, inadequate surgical specimen, pt withdrawal, 
protocol violation, etc.). The tumor proliferation measured by FLT-PET 
was correlated well with Ki-67 values. The correlation coefﬁcient(ρ) 
between SUVs using FLT-PET and Ki-67 values was 0.6416, and it was 
signiﬁcantly greater than 0.5 (p<0.05). In subgroup analyses, ρ was 
0.7305 (p<0.05) in tumors ≤ 3 cm in size, while it was 0.4570 (p>0.05) 
in tumors > 3 cm in size. In all 110 pts, 10 mild or moderate adverse 
reactions were recorded, but no reaction was considered to be related to 
FLT and all pts recovered. 
Conclusions: FLT-PET is an effective and safe imaging method to 
measure tumor proliferation in vivo.
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Background: Erlotinib is an inhibitor of epidermal growth factor re-
ceptor tyrosine kinase (EGFR-TK) approved for treatment of refractory 
non-small cell lung cancer (NSCLC). Preclinical studies indicate that 
EGFR-TK inhibitors enhance the effects of ionizing radiation. We per-
formed this Phase I trial to determine the maximum tolerated dose of 
erlotinib that can be administered with two standard chemoradiotherapy 
approaches for NSCLC. 
Methods: Patients with unresectable stage III NSCLC were en-
rolled in this 2-arm dose-escalation study. Arm A (SWOG 9504) 
included chemoradiotherapy with cisplatin(50mg/m2 IV d1,8,29,36), 
etoposide(50mg/m2 IV d1-5,29-33), chest radiation therapy (2Gy/
day, total 66Gy) and daily oral erlotinib for 7 weeks followed by 
docetaxel (75mg/m2 IV Q21d) for 3 cycles. Arm B (CALGB 39801) 
included induction paclitaxel (200mg/m2 d1) & carboplatin (AUC 6 
d1) for two 21-day cycles then chest radiation therapy with weekly 
paclitaxel(50mg/m2), weekly carboplatin (AUC=2) and daily erlotinib 
for 7 weeks. In both arms, the erlotinib dose was escalated from 50 to 
150mg/day in cohorts of 3-6 patients. Erlotinib was given only during 
concomitant chemoradiotherapy.
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Results: Thirty-four patients were enrolled and treated. Patient 
characteristics were: ECOG performance status 0 in 24 patients, 1 in 
10 patients, median age 63 years (range 39-78), and gender male 20, 
female 14. Dose-escalation was possible to erlotinib 150mg/day for 
both regimens during chemoradiotherapy. Grade 3/4 leukopenia and 
neutropenia were noted in both arms. No Grade 4 therapy-related non-
hematologic toxicities were noted. For arm A, grade 3 toxicities during 
chemoradiotherapy were: esophagitis (3), vomiting (1), ototoxicity (1), 
diarrhea (2), dehydration (3), pneumonitis (1). For arm B, esophagitis 
(6) was the dominant grade 3 toxicity. Rash developed in 7 patients 
(21%). Twenty-seven patients (79%) completed their assigned regimen 
and were evaluable for response (Arm A - 12, Arm B - 15). Reasons 
for discontinuation were: adverse event (3), withdrawal of consent (2), 
non-compliance (1) and non-cancer related early death (1). Overall 
radiologic responses were (Arm A/B): Complete Response (0/1), 
Partial Response (8/9), Stable Disease (1/2) and Progressive Disease 
(3/3). Intention-to-treat 1- and 2- overall survivals were 47% and 21%, 
respectively. Overall and median survivals between the two arms were 
not signiﬁcantly different. In the patients who developed a rash (7), 1 
complete and 4 partial responses were observed. This group of patients 
had a trend towards improved overall survival (log-rank 0.07).
Conclusion: The addition of erlotinib to two standard chemoradio-
therapy regimens is feasible and does not increase toxicities associated 
with chemoradiotherapy.
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Background: Neither the optimal sequence of treatment nor the best 
combination CT is yet well-deﬁned in p receiving concomitant therapy. 
Methods: P with unresectable stage III NSCLC with IK > 70 and 
weight loss < 5% were initially randomized to sequential treatment 
(arm A), concurrent CT/TRT followed by consolidation (C) CT (arm 
B) or induction (I) CT followed by CT/TRT (arm C). Based on RTOG 
9410 results, arm A was closed and the study continues with two 
concomitant arms (B, C). All p receive 2 cycles of Docetaxel (D) 40 
mg/m2 d1, 8 plus Gemcitabine (G) 1200 mg/m2 d1, 8 as I or C therapy. 
Concomitant treatment includes D 20 mg/m2 and carboplatin (Cb) AUC 
2 weekly plus 60 Gy TRT. 
Results: From May 01 to Jun 06, 151 p were included (A: 19, B: 66, C: 
66). Due to the early closing of arm A, only data of evaluable arms B 
and C p are shown: toxicity 127 p (B: 63, C: 64) and response 110 p (B: 
53, C: 57). All groups are well-matched for baseline disease character-
istics. Toxicity grade 3-4 by CTC and RTOG criteria was: esophagitis 
19.5% (arm B) and 14.2% (arm C); pneumonitis 8.8 % (arm B) and 
10% (arm C). Neutropenia during I or C therapy: 22 % (B) and 6.2 
% (C). Thrombocytopenia 8% (B) and 3% (C). Neutropenia during 
concomitant therapy: 6.3% (B) and 6% (C). No thrombocytopenia or 
severe anemia was found during CT/TRT. The reduction CT rate was 
superior in consolidation (35%) than in induction (15%) and in arm C 
during concomitant therapy (22.4% C, 6.5% B). Delay of CT dose was 
similar in B and C arms during I or C (22% B, 20% C) but superior 
in arm C during concurrent treatment (19.6% B, 30.6% C). The ﬁnal 
response rates were 57% (B) and 56.9% (C). A trend for longer time to 
progression (TTP) was found (B: 7.6 months (m) and C: 9.2 m; p= 0.12) 
but with similar overall survival (B: 14.3 m and C: 14.7 m; p= 0.38). 
Conclusions: Non-platinum CT plus concomitant chemoradiation offer 
similar response rate and a favorable hematological toxicity proﬁle in 
unresectable stage III NSCLC p. No differences in OS but a trend for 
longer TTP in the arm C (I followed by concurrent approach) has been 
found. Final data are pending in order to select the best sequence for 
further studies.
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Background: Combined modality therapy using both chemotherapy 
and TRT is the standard treatment option in unrectable stage III 
NSCLC. Our group demonstrated a superiority of MVP with concur-
rent TRT over that with sequential TRT (Furuse et al. JCO 17, 1999). 
Currently, concurrent chemoradiotherapy plays a pivotal role in this pa-
tient population. However, the optimal chemotherapy regimen remains 
unclear. Weekly chemotherapy with concurrent TRT has acceptable 
toxicities and expected efﬁcacy. We conducted a randomized phase III 
trial to compare the efﬁcacy and toxicity of weekly chemotherapy with 
concurrent TRT against MVP by a non-inferiority design. 
Methods: Patients (pts) were randomly assigned to 3 regimens; MVP: 
cisplatin (80 mg/m2 on days 1, 29), vindesine (3 mg/m2 on days 1, 8, 
29, 36) and mitomycin (8 mg/m2 on days 1, 29) with concurrent TRT 
(60 Gy). After then, pts received 2 courses of consolidation chemo-
therapy with MVP; IC: weekly irinotecan (20 mg/m2)/carboplatin(AUC 
2) for 6 weeks and TRT (60 Gy) followed by 2 courses of irinotecan(50 
mg/m2)/carboplatin(AUC 5); PC: weekly paclitaxel (40 mg/m2)/carbo-
platin (AUC 2) and TRT (60 Gy) followed by 2 courses of paclitaxel 
(200 mg/m2)/carboplatin (AUC 5). The primary endpoint was overall 
survival; secondary endpoints were time to progression, response, and 
toxicity. 
Results: From Sep 2001 to Sep 2005, 456 pts were randomized; 429 
pts had evaluated responses. Pretreatment characteristics were well-bal-
anced between 3 arms (median age 63 years (30-74), PS0/1 41/55 %, 
Ad/Sq /others 43/ 45/12 %). The achievement rates of full treatment in 
MVP, IC and PC were 39.9, 29.7, and 49.3 %; those of full-dose TRT / 
